The elusive promise of myostatin inhibition for muscular dys... : Current Opinion in Neurology
The elusive promise of myostatin inhibition for muscular dystrophy : Current Opinion in …

Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is
highly expressed in skeletal muscle, was first described in 1997. It has been known that loss …

In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …

Genetic deletion of Myostatin, a member of the Transforming Growth Factor-beta family of
signalling molecules, resulted in excessive growth of skeletal muscle. It demonstrated the …

Objective Myostatin is an endogenous negative regulator of muscle growth and a novel
target for muscle diseases. We conducted a safety trial of a neutralizing antibody to …

Myostatin is a negative regulator of muscle mass. Important advances in our understanding
of the complex biology of this factor have revealed the therapeutic potential of antagonizing …

Skeletal muscle is the largest organ in the human body, and plays an important role in body
movement and metabolism. Skeletal muscle mass is lost in genetic disorders such as …

A decade has passed since myostatin was first identified as a negative regulator of muscle
growth. Since then, studies in both humans and animals have demonstrated that decreasing …

Myostatin is a secreted protein that negatively regulates skeletal muscle mass determining
both muscle fiber number and size. The myostatin pathway is conserved and regulates …

In addition to gene correction therapy and cell transplantation techniques, multidisciplinary
approaches to drug discovery and development offer promising therapeutic strategies for …